<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="mga3" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">mga3</book-part-id>
      <title-group>
        <title><italic toggle="yes">OPA3</italic>-Related 3-Methylglutaconic Aciduria</title>
        <alt-title alt-title-type="alt-title">Synonyms: Costeff Syndrome, Optic Atrophy Plus Syndrome, Costeff Optic Atrophy Syndrome, 3-Methylglutaconic Aciduria Type 3</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Gunay-Aygun</surname>
            <given-names>Meral</given-names>
          </name>
          <xref ref-type="aff" rid="mga3.AFF1"/>
          <degrees>MD</degrees>
          <email>mgaygun@mail.nih.gov</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Huizing</surname>
            <given-names>Marjan</given-names>
          </name>
          <xref ref-type="aff" rid="mga3.AFF2"/>
          <degrees>PhD</degrees>
          <email>mhuizing@mail.nih.gov</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Anikster</surname>
            <given-names>Yair</given-names>
          </name>
          <xref ref-type="aff" rid="mga3.AFF3"/>
          <degrees>MD, PhD</degrees>
          <email>yair.anikster@sheba.health.gov.il</email>
        </contrib>
      </contrib-group>
      <aff id="mga3.AFF1">National Human Genome Research Institute<break/>Medical Genetics Branch<break/>Section on Human Biochemical Genetics<break/>National Institutes of Health<break/>Bethesda, Maryland <break/>Associate Professor of Pediatrics and Genetics, Institute of Genetic Medicine<break/>Departments of Pediatrics and Genetics <break/>Johns Hopkins University School of Medicine <break/>Baltimore, Maryland</aff>
      <aff id="mga3.AFF2">National Human Genome Research Institute<break/>Medical Genetics Branch<break/>Section on Human Biochemical Genetics<break/>National Institutes of Health<break/>Bethesda, Maryland </aff>
      <aff id="mga3.AFF3">Head of Metabolic Unit, Safra Children's Hospital<break/>Sheba Medical Center <break/>Tel Hashomer, Israel</aff>
      <pub-history>
        <date iso-8601-date="2006-07-28" date-type="created">
          <day>28</day>
          <month>07</month>
          <year>2006</year>
        </date>
        <date iso-8601-date="2013-12-19" date-type="updated">
          <day>19</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="leigh-nucl-ov" document-type="chapter">Nuclear Gene-Encoded Leigh Syndrome Overview</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="dfnb9" document-type="chapter"><italic toggle="yes">OTOF</italic>-Related Deafness</related-object>
      <abstract id="mga3.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria is characterized by optic atrophy and/or choreoathetoid movement disorder with onset before age ten years. Optic atrophy is associated with progressive, decreased visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. Although most individuals develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria is suggested by elevated urinary excretion of 3-methylglutaconate (3-MGC) and 3-methylglutaric acid (3-MGA) and confirmed by identification of biallelic <italic toggle="yes">OPA3</italic> pathogenic variants. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Supportive and often provided by a multidisciplinary team; treatment of visual impairment, spasticity, and movement disorder as in the general population. </p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Use of tobacco, alcohol, and medications known to impair mitochondrial function.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="mga3.Diagnosis">
        <title>Diagnosis</title>
        <p><bold>The diagnosis of <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria is suspected</bold> in a child with relatively normal early development and growth in combination with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bilateral early-onset optic atrophy</p>
          </list-item>
          <list-item>
            <p>Choreoathetoid movement disorder</p>
          </list-item>
        </list>
        <p>Note: Progressive spasticity, cerebellar ataxia, and cognitive deterioration are variably seen in affected children and more commonly at later stages.</p>
        <p>
          <bold>The diagnosis is confirmed by documentation of:</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Increased urinary excretion of (3-MGC) and 3-methylglutaric acid (3-MGA).</bold> 3-MGC and 3-MGA are measured in the urine using gas chromatography-mass spectrometry (GC-MS). In <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, urinary 3-MGC and 3-MGA are mildly increased (combined elevation &#x0003c;200 mmol/mol creatinine) (<xref ref-type="table" rid="mga3.T.combined_urinary_excretion_of_3mg">Table 1</xref>).Note: (1) 3-MGA is derived from hydrogenation of 3-methylglutaconyl-CoA. (2) Individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria have normal laboratory values for the following:</p>
          </list-item>
          <list-item>
            <p>Serum bicarbonate concentration</p>
          </list-item>
          <list-item>
            <p>Liver and kidney function tests</p>
          </list-item>
          <list-item>
            <p>Serum and cerebrospinal fluid (CSF) lactic acid concentrations</p>
          </list-item>
          <list-item>
            <p>Serum creatinine phosphokinase (CK) activity</p>
          </list-item>
        </list>
        <table-wrap id="mga3.T.combined_urinary_excretion_of_3mg" position="anchor" orientation="portrait">
          <label>Table 1.</label>
          <caption>
            <p>Combined Urinary Excretion of 3-MGC and 3-MGA in <italic toggle="yes">OPA3</italic>-Related 3-Methylglutaconic Aciduria</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1">Phenotype</th>
                <th id="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">Combined Urinary Excretion: Range</th>
              </tr>
              <tr>
                <th headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2" id="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">In mmol/mol Creatinine</th>
                <th headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2" id="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">In &#x000b5;mol/L</th>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria</td>
                <td headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">9-187</td>
                <td headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">141-2245</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Normal controls</td>
                <td headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">3.2-7</td>
                <td headers="hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_b_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">20-98</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="mga3.TF.1">
              <p>In a study of 39 individuals </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <list list-type="bullet">
          <list-item>
            <p>
              <bold>Biallelic pathogenic variants in <italic toggle="yes">OPA3</italic></bold>
            </p>
          </list-item>
          <list-item>
            <p>If clinical findings point to <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria and urinary excretion of 3-MGC and 3-MGA is elevated, the diagnosis can be confirmed by molecular genetic testing of <italic toggle="yes">OPA3</italic>.</p>
          </list-item>
          <list-item>
            <p>Because the excretion of 3-MGC and 3-MGA is variable among individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria (sometimes even overlapping that of normal controls) and is not always easy to detect on urine organic acid analysis, molecular genetic testing should be used in individuals whose findings otherwise strongly suggest <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria.</p>
          </list-item>
          <list-item>
            <p>To date, the <xref ref-type="table" rid="mga3.T.selected_opa3_variants">c.143-1G&#x0003e;C</xref> pathogenic variant has been identified in all affected individuals of Iraqi Jewish descent. Thus, targeted mutation analysis for the <xref ref-type="table" rid="mga3.T.selected_opa3_variants">c.143-1G&#x0003e;C</xref> variant should be performed first in affected individuals of Iraqi Jewish origin.</p>
          </list-item>
        </list>
        <table-wrap id="mga3.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
          <label>Table 2.</label>
          <caption>
            <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">OPA3</italic>-Related 3-Methylglutaconic Aciduria</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                <th id="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_2">Test Method</th>
                <th id="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3" colspan="2" align="left" valign="middle" rowspan="1">Proportion of Probands with a Pathogenic Variant Detectable by this Method</th>
              </tr>
              <tr>
                <th headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3" id="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">Iraqi Jewish</th>
                <th headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3" id="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">Non-Iraqi Jewish</th>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_1" align="left" valign="middle" rowspan="3" colspan="1">
                  <italic toggle="yes">OPA3</italic>
                </td>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Targeted mutation analysis&#x000a0;<sup>2</sup></td>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3 hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">See footnote 3</td>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3 hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">See footnote 4</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup></td>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3 hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_1 hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_2" colspan="2" align="left" valign="middle" rowspan="1">Unknown</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                <td headers="hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_1_3 hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_1 hd_b_mga3.T.summary_of_molecular_genetic_test_1_1_2_2" colspan="2" align="left" valign="middle" rowspan="1">Unknown&#x000a0;<sup>7</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="mga3.TF.2">
              <label>1.</label>
              <p>See <related-object source-id="gene" document-id="mga3" object-id="mga3.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="mga3.Resources">Molecular Genetics</xref> for information on allelic variants detected in this gene. </p>
            </fn>
            <fn id="mga3.TF.2.1">
              <label>2.</label>
              <p>Mutation panels may vary by laboratory. </p>
            </fn>
            <fn id="mga3.TF.2.2">
              <label>3.</label>
              <p>The variant <xref ref-type="table" rid="mga3.T.selected_opa3_variants">c.143-1G&#x0003e;C</xref> accounts for 100% of pathogenic variants in the Iraqi Jewish population [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>]. </p>
            </fn>
            <fn id="mga3.TF.2.3">
              <label>4.</label>
              <p>The variant <xref ref-type="table" rid="mga3.T.selected_opa3_variants">c.320_337del</xref>, found in an individual of Turkish-Kurdish origin with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, is the first pathogenic variant found to date in an individual of non-Iraqi Jewish origin [<xref ref-type="bibr" rid="mga3.REF.kleta.2002.201">Kleta et al 2002</xref>]. The nonsense variant <xref ref-type="table" rid="mga3.T.selected_opa3_variants">c. 415C&#x0003e;T</xref> (p.Gln139Ter), found in the homozygous state in an individual of Indian origin with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, is the second pathogenic variant found to date in an individual of non-Iraqi Jewish origin [<xref ref-type="bibr" rid="mga3.REF.ho.2008.S419">Ho et al 2008</xref>]. </p>
            </fn>
            <fn id="mga3.TF.2.4">
              <label>5.</label>
              <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
            </fn>
            <fn id="mga3.TF.2.5">
              <label>6.</label>
              <p>Testing that identifies exonic or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
            </fn>
            <fn id="mga3.TF.2.6">
              <label>7.</label>
              <p>To date, no deletions or duplications involving <italic toggle="yes">OPA3</italic> have been reported to cause <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria; however, a systematic analysis has yet to be performed. </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="mga3.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="mga3.Natural_History">
          <title>Clinical Description</title>
          <p>Most individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria present within the first ten years of life with decreased visual acuity and/or choreoathetoid movement disorder. Although most develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable.</p>
          <p><bold>Optic atrophy</bold> manifests as decreased visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. The optic discs are pathologically pale, and the papillary vasculature is attenuated. Visual evoked potentials reveal bilateral prolonged latencies consistent with optic atrophy.</p>
          <p>In 36 individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, visual acuity decreased with age: </p>
          <list list-type="bullet">
            <list-item>
              <p>In two children age two years, visual acuity appeared to be normal.</p>
            </list-item>
            <list-item>
              <p>In 14 individuals age three to 21 years (14.2&#x000b1;5.5), visual acuity was 6/21 or less.</p>
            </list-item>
            <list-item>
              <p>In 20 individuals age five to 37 years (18&#x000b1;9.5), visual acuity was 3/60 or less.</p>
            </list-item>
          </list>
          <p>Some children have strabismus and gaze apraxia.</p>
          <p>The electroretinogram (ERG) is normal.</p>
          <p><bold>Extrapyramidal dysfunction and spasticity</bold> cause most of the observed motor disability.</p>
          <p>Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. In 36 individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, extrapyramidal signs:</p>
          <list list-type="bullet">
            <list-item>
              <p>Caused major disability in 17 individuals age two to 37 years (mean 16.1&#x000b1;17.8)</p>
            </list-item>
            <list-item>
              <p>Caused minor disability in maintaining stable posture and fine motor activities in 12 individuals age two to 26 years (11.7&#x000b1;8.1)</p>
            </list-item>
            <list-item>
              <p>Caused mild symptoms with no resulting disability in three individuals age 15 to 36 years</p>
            </list-item>
            <list-item>
              <p>Were absent in four individuals ages 13 to 32 years</p>
            </list-item>
          </list>
          <p>Unstable spastic gait, increased tendon reflexes, and positive Babinski sign may be seen. In 36 individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, spasticity was age-related:</p>
          <list list-type="bullet">
            <list-item>
              <p>Nine individuals age two to 12 years (5.9&#x000b1;3.5) did not have spasticity.</p>
            </list-item>
            <list-item>
              <p>Four individuals age 11 to 26 years had mild spasticity but no related disability.</p>
            </list-item>
            <list-item>
              <p>Eleven individuals age 13 to 37 years (21.4&#x000b1;9.3) had mild spasticity-related disability.</p>
            </list-item>
            <list-item>
              <p>Twelve individuals age nine to 26 years (17.0&#x000b1;4.8) had severe spasticity-related disability.</p>
            </list-item>
          </list>
          <p><bold>Cerebellar dysfunction</bold> is usually mild. Ataxia and dysarthria causing mostly mild disability were detected in 18 of the 36 individuals reported by <xref ref-type="bibr" rid="mga3.REF.elpeleg.1994.167">Elpeleg et al [1994]</xref>.</p>
          <p><bold>Cognitive impairment</bold> is seen in some individuals. Of 36 individuals:</p>
          <list list-type="bullet">
            <list-item>
              <p>Nineteen individuals age two to 36 years (16.&#x000b1;18.7) had an IQ of &#x02265;71.</p>
            </list-item>
            <list-item>
              <p>Thirteen individuals age two to 37 years (14.7&#x000b1;9.2) had an IQ between 55 and 71.</p>
            </list-item>
            <list-item>
              <p>Four individuals age nine to 26 years had an IQ between 40 and 54 </p>
            </list-item>
          </list>
          <p><bold>Other.</bold> Affected adults in the fourth decade of life have been reported; life expectancy beyond the fourth decade is unknown.</p>
          <p>Cranial nerve functions, sensation, and muscle tone are normal.</p>
          <p>Seizures are not typical in <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria. Partial seizures were reported in one individual.</p>
          <p>Individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria have no cardiac or structural brain abnormalities.</p>
          <p>The level of 3-methylglutaconate (3-MGC) or 3-methylglutaric acid (3-MGA) in urine does not correlate with the degree of neurologic damage.</p>
        </sec>
        <sec id="mga3.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The limited number of pathogenic variants found to date does not permit genotype-phenotype correlations.</p>
          <p>All individuals of Iraqi Jewish origin with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria have the same pathogenic variant; however, the phenotypic severity varies, even within the same family.</p>
        </sec>
        <sec id="mga3.Prevalence">
          <title>Prevalence</title>
          <p><italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria has been reported in approximately 40 individuals of Iraqi Jewish origin [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>] and in one individual of Kurdish-Turkish descent [<xref ref-type="bibr" rid="mga3.REF.kleta.2002.201">Kleta et al 2002</xref>].</p>
          <p>The carrier rate in Iraqi Jews is estimated to be 1:10 [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>].</p>
        </sec>
      </sec>
      <sec id="mga3.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Two heterozygous <italic toggle="yes">OPA3</italic> pathogenic variants, <xref ref-type="table" rid="mga3.T.selected_opa3_variants">p.Gly93Ser</xref> and <xref ref-type="table" rid="mga3.T.selected_opa3_variants">p.Gln105Glu</xref>, were reported in two families with autosomal dominant optic atrophy and cataract [<xref ref-type="bibr" rid="mga3.REF.reynier.2004.e110">Reynier et al 2004</xref>]. </p>
      </sec>
      <sec id="mga3.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
          <bold>Disorders in which excretion of 3-methylglutaconate (3-MGC) is increased</bold>
        </p>
        <p>Increased urinary excretion of the branched-chain organic acid 3-methylglutaconate (3-MGC) is a relatively common finding in children investigated for suspected inborn errors of metabolism [<xref ref-type="bibr" rid="mga3.REF.gunayaygun.2005.1">Gunay-Aygun 2005</xref>]. 3-MGC is an intermediate of leucine degradation and the mevalonate shunt pathway that links sterol synthesis with mitochondrial acetyl-CoA metabolism (<xref ref-type="fig" rid="mga3.F1">Figure 1</xref>). </p>
        <p>Classification of inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature has recently been updated by <xref ref-type="bibr" rid="mga3.REF.wortmann.2013a.923">Wortmann et al [2013a]</xref> and <xref ref-type="bibr" rid="mga3.REF.wortmann.2013b.913">Wortmann et al [2013b]</xref> (<xref ref-type="table" rid="mga3.T.new_classification_for_inborn_err">Table 3</xref>). Clinical features (<xref ref-type="table" rid="mga3.T.new_classification_for_inborn_err">Table 3</xref>) and biochemical findings (<xref ref-type="table" rid="mga3.T.urinary_excretion_of_3mgc_and_3mg">Table 4</xref>) of the 3-MGCA syndromes vary. Tissues with higher requirements for oxidative metabolism, such as the central nervous system and cardiac and skeletal muscle, are predominantly affected.</p>
        <p>To explore whether pathogenic variants in <italic toggle="yes">OPA3</italic> are present in individuals with nonspecific neurologic abnormalities and unexplained 3-MGCA, 11 individuals were screened; none were found to have pathogenic variants, suggesting that mutation of <italic toggle="yes">OPA3</italic> is not a common cause of 3-MGCA in the absence of typical clinical features of <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria [<xref ref-type="bibr" rid="mga3.REF.neas.2005.525">Neas et al 2005</xref>].</p>
        <p>Five forms of 3-methylglutaconic aciduria (3-MGCA) have been recognized (<xref ref-type="table" rid="mga3.T.new_classification_for_inborn_err">Table 3</xref>) [<xref ref-type="bibr" rid="mga3.REF.sweetman.2001.1">Sweetman &#x00026; Williams 2001</xref>, <xref ref-type="bibr" rid="mga3.REF.gunayaygun.2005.1">Gunay-Aygun 2005</xref>, <xref ref-type="bibr" rid="mga3.REF.wortmann.2013a.923">Wortmann et al 2013a</xref>, <xref ref-type="bibr" rid="mga3.REF.wortmann.2013b.913">Wortmann et al 2013b</xref>]. The exact source of 3-MGC is known in only 3-methylglutaconyl-CoA hydratase deficiency, the rarest of the five types, caused by primary deficiency of the mitochondrial enzyme 3-methylglutaconyl-CoA hydratase (3-MGCH), resulting in a block of leucine degradation.</p>
        <table-wrap id="mga3.T.new_classification_for_inborn_err" position="anchor" orientation="portrait">
          <label>Table 3.</label>
          <caption>
            <p>New Classification for Inborn Errors of Metabolism with 3-Methylglutaconic Aciduria as Discriminative Feature</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Patho-Mechanism</th>
                <th id="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Disease Name</th>
                <th id="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Former Designation</th>
                <th id="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Additional Hallmarks&#x000a0;<sup>1</sup> of Phenotype</th>
                <th id="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">Mode of Inheritance</th>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1 hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">
                  <bold>Primary 3-MGA-uria</bold>
                </td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1"/>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1"/>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Organic aciduria</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">3-methylglutaconyl-CoA hydratase deficiency (<italic toggle="yes">AUH</italic> defect)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type I<break/>(3-MGCA-1)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Adult onset leukoencephalopathy, dementia, progressive spasticity</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1 hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">
                  <bold>Secondary 3-MGA-uria</bold>
                </td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1"/>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1"/>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1">Defective phospholipid remodeling</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">TAZ</italic> defect (<related-object link-type="booklink" source-id="gene" document-id="barth" document-type="chapter">Barth syndrome</related-object>)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type II (3-MGCA-2)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">(Cardio)myopathy, short stature, neutropenia, hypocholesterolemia, cognitive phenotype, mild dysmorphic features, OXPHOS dysfunction</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">XL</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">SERAC1</italic> defect (<related-object link-type="booklink" source-id="gene" document-id="megdel" document-type="chapter">MEGDEL syndrome</related-object>)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type IV <break/>(3-MGCA-4)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Progressive spasticity, dystonia, deafness, Leigh syndrome-like MRI, severe psychomotor retardation, hypocholesterolemia, OXPHOS dysfunction</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1" align="left" valign="middle" rowspan="3" colspan="1">Mitochondrial membrane disorder</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">OPA3</italic> defect (Costeff syndrome)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type III <break/>(3-MGCA-3)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Ataxia/extrapyramidal dysfunction, optic atrophy</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">TMEM70</italic> defect</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type IV<break/>(3-MGCA-4)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Broad phenotype, hypertrophic cardiomyopathy, myopathy, dysmorphic features, cataracts, psychomotor retardation, ATPase deficiency, lactic acidosis, hyperammonemia</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">DNAJC19</italic> defect (DCMA syndrome)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type V (3-MGCA-5)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Dilated cardiomyopathy, ECG abnormalities, non-progressive cerebellar ataxia, Small atrophic testes, <break/>cryptorchidism, growth failure, anemia, steatosis hepatitis</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">NOS 3-MGA-uria</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">3-MGCA type IV<break/>(3-MGCA-4)</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Variable, mostly progressive neurologic disease</td>
                <td headers="hd_b_mga3.T.new_classification_for_inborn_err_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">Unknown</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="mga3.TF.3">
              <p>From <xref ref-type="bibr" rid="mga3.REF.wortmann.2013a.923">Wortmann et al [2013a]</xref>. Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="PDF File" xlink:href="mga3-Table3a.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for an expanded version of the table with information on protein subcellular localization and function.</p>
            </fn>
            <fn id="mga3.TF.3.1">
              <p>DCMA = dilated cardiomyopathy with ataxia; NOS= not otherwise specified</p>
            </fn>
            <fn id="mga3.TF.3.2">
              <p>1. In addition to 3-MGA-uria</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="mga3.T.urinary_excretion_of_3mgc_and_3mg" position="anchor" orientation="portrait">
          <label>Table 4.</label>
          <caption>
            <p>Urinary Excretion of 3-MGC and 3-MGA in Inborn Errors of Metabolism with 3-Methylglutaconic Aciduria</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1">Disorder</th>
                <th id="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2" colspan="2" align="left" valign="middle" rowspan="1">Urinary Excretion</th>
              </tr>
              <tr>
                <th headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2" id="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">3-MGC and 3-MGA in mmol/mol Creatinine</th>
                <th headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2" id="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">3-Hydroxyisovaleric Acid <break/>(3-HIV)</th>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">3-methylglutaconyl-CoA hydratase deficiency</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">500 to 1000&#x000a0;<sup>1</sup></td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">Increased</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">TAZ</italic> defect (<related-object link-type="booklink" source-id="gene" document-id="barth" document-type="chapter">Barth syndrome</related-object>)</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">Mild to moderate&#x000a0;<sup>2</sup></td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">OPA3</italic> defect (Costeff syndrome)&#x000a0;<sup>3</sup>
</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">9-187</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">DNAJC19</italic> defect (DCMA syndrome)</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">Moderate&#x000a0;<sup>4</sup></td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">NOS 3-MGA-uria</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">Elevated to variable degrees</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Normal controls</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">3.2-7</td>
                <td headers="hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_b_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="mga3.TF.4">
              <label>1.</label>
              <p>The urinary excretion of 3-methylglutaric acid (3-MGA) correlates with protein intake, whereas, in most individuals with other types of 3-MGCA the amount of 3-MGC in urine is not dependent on dietary leucine [<xref ref-type="bibr" rid="mga3.REF.sweetman.2001.1">Sweetman &#x00026; Williams 2001</xref>].</p>
            </fn>
            <fn id="mga3.TF.4.1">
              <label>2.</label>
              <p>Less than ten times the upper limit of normal</p>
            </fn>
            <fn id="mga3.TF.4.2">
              <label>3.</label>
              <p>In 39 individuals [<xref ref-type="bibr" rid="mga3.REF.elpeleg.1994.167">Elpeleg et al 1994</xref>]</p>
            </fn>
            <fn id="mga3.TF.4.3">
              <label>4.</label>
              <p>Five- to tenfold normal [<xref ref-type="bibr" rid="mga3.REF.davey.2006.385">Davey et al 2006</xref>]</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>3-methylglutaconyl-CoA hydratase deficiency.</bold> The clinical features include nonspecific speech and language delay without metabolic derangement in some individuals and with hypoglycemia and metabolic acidosis in others (<xref ref-type="table" rid="mga3.T.new_classification_for_inborn_err">Table 3</xref>). Failure to thrive and psychomotor retardation are common. Microcephaly and progressive neurologic impairment with spastic quadriplegia, seizures, and dystonia have been reported. [<xref ref-type="bibr" rid="mga3.REF.sweetman.2001.1">Sweetman &#x00026; Williams 2001</xref>, <xref ref-type="bibr" rid="mga3.REF.ijlst.2002.1463">Ijlst et al 2002</xref>, <xref ref-type="bibr" rid="mga3.REF.illsinger.2004.213">Illsinger et al 2004</xref>].</p>
        <p><bold><italic toggle="yes">TAZ</italic> defect (</bold><related-object link-type="booklink" source-id="gene" document-id="barth" document-type="chapter"><bold>Barth syndrome</bold></related-object><bold>).</bold> The clinical features include dilated cardiomyopathy associated with skeletal myopathy, neutropenia, and growth retardation (<xref ref-type="table" rid="mga3.T.new_classification_for_inborn_err">Table 3</xref>) [<xref ref-type="bibr" rid="mga3.REF.walsh.1999.251">Walsh et al 1999</xref>, <xref ref-type="bibr" rid="mga3.REF.ijlst.2002.1463">Ijlst et al 2002</xref>, <xref ref-type="bibr" rid="mga3.REF.barth.2004.349">Barth et al 2004</xref>]. Dilated cardiomyopathy presents within the first year of life or even prenatally [<xref ref-type="bibr" rid="mga3.REF.barth.2004.349">Barth et al 2004</xref>]. Cognitive development is normal, although an associated learning disorder has been described. </p>
        <p>Moderately decreased plasma cholesterol (mostly of the LDL type) may be another clue for diagnosis of Barth syndrome.</p>
        <p><italic toggle="yes">TAZ</italic> defect cannot always be distinguished from <italic toggle="yes">OPA3</italic> defect (Costeff syndrome) by urinary organic acid results alone (<xref ref-type="table" rid="mga3.T.urinary_excretion_of_3mgc_and_3mg">Table 4</xref>).</p>
        <p><bold><italic toggle="yes">DNAJC19</italic> defect (DCMA syndrome).</bold> DCMA, seen in the Dariusleut Hutterite population of Canada [<xref ref-type="bibr" rid="mga3.REF.davey.2006.385">Davey et al 2006</xref>] is characterized by severe early-onset dilated cardiomyopathy, growth failure, and cerebellar ataxia. Some may have optic atrophy. The mode of inheritance and the lack of skeletal myopathy and neutropenia distinguish DCMA syndrome from Barth syndrome.</p>
        <p><bold>Not otherwise specified 3-MGA-uria type</bold> (former <bold>3-MGCA 4)</bold> includes all other individuals with 3-MGCA with normal 3-methylglutaconyl-CoA hydratase enzyme activity, and no defect in <italic toggle="yes">TAZ, SERAC1, OPA3, TMEM70</italic>, or <italic toggle="yes">DNAJC19</italic> [<xref ref-type="bibr" rid="mga3.REF.sweetman.2001.1">Sweetman &#x00026; Williams 2001</xref>, <xref ref-type="bibr" rid="mga3.REF.gunayaygun.2005.1">Gunay-Aygun 2005</xref>]. Most individuals in this group present early in life with nonspecific neurologic findings including psychomotor retardation and muscle tone abnormalities. Cardiomyopathy is common. Some have microcephaly, hearing loss, and retinitis pigmentosa, optic atrophy and/or cataracts. Some asymptomatic adults and pregnant women have been reported. Two brothers with a neurodegenerative disorder also had a myelodysplastic syndrome [<xref ref-type="bibr" rid="mga3.REF.arn.2006.62">Arn &#x00026; Funanage 2006</xref>, <xref ref-type="bibr" rid="mga3.REF.haimi.2006.69">Haimi et al 2006</xref>]. Persistent and episodic lactic acidosis are common. Some individuals have increased excretion of citric acid cycle intermediates.</p>
        <p><bold>Differential diagnosis of the clinical findings of <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria (Costeff syndrome)</bold>
</p>
        <p><bold>Optic atrophy</bold> is seen in a number of syndromes as part of a complex phenotype. The combination of ataxia and optic atrophy is relatively nonspecific.</p>
        <p>Pathologic pallor of optic atrophy may sometimes be difficult to differentiate from the physiologic optic disc pallor of infancy.</p>
        <p><bold>Behr syndrome.</bold> The clinical picture of Behr syndrome is most similar to <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria [<xref ref-type="bibr" rid="mga3.REF.copeliovitch.2001.512">Copeliovitch et al 2001</xref>]. Behr syndrome is an autosomal recessive disorder of childhood-onset optic atrophy and spinocerebellar degeneration characterized by ataxia, spasticity, intellectual disability, posterior column sensory loss, and peripheral neuropathy [OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/210000">210000</ext-link>]. Ataxia, an obligatory finding in Behr syndrome, is not seen in approximately half of individuals with <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria; conversely, most individuals with Behr syndrome do not manifest extrapyramidal dysfunction, one of the major features of <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria. Given that some individuals with <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria do not have extrapyramidal dysfunction, it is not possible to distinguish Behr syndrome from <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria based on clinical findings alone. At this time, <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria is distinguished from Behr syndrome by the presence of elevated excretion of 3-MGC and 3-MGA in urine (<xref ref-type="table" rid="mga3.T.urinary_excretion_of_3mgc_and_3mg">Table 4</xref>). It is possible that these two disorders are actually the same entity. It remains to be determined if individuals with Behr syndrome without elevated 3-MGA and 3-MGC excretion have mutation of <italic toggle="yes">OPA3</italic>. </p>
        <p><bold>Cerebral palsy.</bold> As the neurologic symptoms of <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria are relatively slow to progress, especially if the optic atrophy is not recognized, the disorder may be misdiagnosed as cerebral palsy [<xref ref-type="bibr" rid="mga3.REF.straussberg.1998.54">Straussberg et al 1998</xref>]. Therefore, cerebral palsy-like symptoms accompanied by optic atrophy and extrapyramidal signs in the absence of systemic acidosis should call for determination of urinary 3-MGC.</p>
      </sec>
      <sec id="mga3.Management">
        <title>Management</title>
        <sec id="mga3.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria (Costeff syndrome), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete ophthalmologic examination </p>
            </list-item>
            <list-item>
              <p>Visual evoked potentials</p>
            </list-item>
            <list-item>
              <p>Complete neurologic examination</p>
            </list-item>
            <list-item>
              <p>Developmental/educational assessment</p>
            </list-item>
            <list-item>
              <p>Echocardiogram</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation </p>
            </list-item>
          </list>
        </sec>
        <sec id="mga3.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment is supportive.</p>
          <p>A multidisciplinary team including a neurologist, orthopedic surgeon, ophthalmologist, biochemical geneticist, and physical therapist is required for the care of affected individuals.</p>
          <p>Visual impairment, spasticity, and movement disorder should be treated as in the general population.</p>
        </sec>
        <sec id="mga3.Surveillance">
          <title>Surveillance</title>
          <p>Ophthalmologic, neurologic, and orthopedic evaluations as needed based on individual findings are appropriate. </p>
        </sec>
        <sec id="mga3.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>Tobacco and alcohol use</p>
            </list-item>
            <list-item>
              <p>Medications known to impair mitochondrial function</p>
            </list-item>
          </list>
        </sec>
        <sec id="mga3.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="mga3.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="mga3.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="mga3.Other">
          <title>Other</title>
          <p>A possible role for coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) has been hypothesized in the treatment of <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria because both 3-methylglutaconate (3-MGC) and CoQ<sub>10</sub> can be produced from DMAPP, an intermediate metabolite in the synthesis of cholesterol [<xref ref-type="bibr" rid="mga3.REF.costeff.1998.33">Costeff et al 1998</xref>]. Therefore, if CoQ<sub>10</sub> production is impaired, more DMAPP would possibly be directed through the mevalonate shunt to 3-methyglutaconyl-CoA production. The findings of significantly lower-than-normal plasma concentrations of CoQ<sub>10</sub> in six individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria, in two individuals with Barth syndrome, and in four individuals with unclassified type 3-MGA-uria support this hypothesis.</p>
          <p>However, administration of CoQ<sub>10</sub> to six individuals with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria showed no clinical benefit or change in the excretion of 3-MGC [<xref ref-type="bibr" rid="mga3.REF.costeff.1998.33">Costeff et al 1998</xref>]. The question of whether initiation of CoQ<sub>10</sub> supplements early in the course of disease would prevent some neurologic damage remains to be answered. </p>
        </sec>
      </sec>
      <sec id="mga3.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="mga3.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="mga3.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutant allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">OPA3</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="mga3.Carrier_Detection">
          <title>Carrier Detection</title>
          <p><bold>Biochemical genetic testing.</bold> Because carriers have normal urinary excretion of 3-methylglutaric acid (3-MGA) and 3-methylglutaconate (3-MGC), carrier status cannot be determined using biochemical genetic testing.</p>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for:</p>
          <list list-type="bullet">
            <list-item>
              <p>At-risk relatives requires prior identification of the pathogenic variants in the family; </p>
            </list-item>
            <list-item>
              <p>Individuals of Iraqi Jewish origin relies on targeted mutation analysis for the <xref ref-type="table" rid="mga3.T.selected_opa3_variants">c.143-1G&#x0003e;C</xref> mutation.</p>
            </list-item>
          </list>
        </sec>
        <sec id="mga3.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers. </p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="mga3.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> If the pathogenic variants have been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks&#x02019; gestation) or chorionic villus sampling (usually performed at ~10-12 weeks&#x02019; gestation).</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Biochemical genetic testing.</bold> Measurement of 3-MGC and 3-MGA in amniotic fluid is not reliable.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified. </p>
        </sec>
      </sec>
      <sec id="mga3.Resources">
        <title>Resources</title>
      </sec>
      <sec id="mga3.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">OPA3</italic> comprises two exons and spans 32 kb of genomic DNA. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="mga3" object-id="mga3.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> A clinically non-significant <italic toggle="yes">OPA3</italic> sequence variant, c.231T&#x0003e;C, was found in 60 of 98 control alleles [<xref ref-type="bibr" rid="mga3.REF.neas.2005.525">Neas et al 2005</xref>].</p>
        <p><bold>Pathogenic allelic variants</bold> (see <xref ref-type="table" rid="mga3.T.selected_opa3_variants">Table 5</xref>)</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>c.143-1G&#x0003e;C.</bold> This homozygous acceptor splice site variant in <italic toggle="yes">OPA3</italic> is the cause of <italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria in all individuals of Iraqi Jewish origin tested to date [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>]. The resulting lack of mRNA expression manifests as the absence of an <italic toggle="yes">OPA3</italic> band on a northern blotting of fibroblasts from affected individuals and as an inability to amplify <italic toggle="yes">OPA3</italic> using the blood cDNA of affected individuals [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>p.Gly93Ser.</bold> A heterozygous c.277G&#x0003e;A point variant in exon 2 of <italic toggle="yes">OPA3</italic>, resulting in a p.Gly93Ser substitution, is identified in the affected members of a French family with autosomal dominant optic atrophy and cataract [<xref ref-type="bibr" rid="mga3.REF.reynier.2004.e110">Reynier et al 2004</xref>]. </p>
          </list-item>
          <list-item>
            <p><bold>p.Gln105Glu.</bold> A heterozygous c.313C&#x0003e;G transversion in exon 2 of <italic toggle="yes">OPA3</italic>, resulting in a p.Gln105Glu substitution, is identified in the affected members of a family with autosomal dominant optic atrophy and cataract [<xref ref-type="bibr" rid="mga3.REF.reynier.2004.e110">Reynier et al 2004</xref>].</p>
          </list-item>
        </list>
        <p>Heterozygous missense pathogenic variants p.Gly93Ser and p.Gln105Glu result in a milder phenotype [<xref ref-type="bibr" rid="mga3.REF.reynier.2004.e110">Reynier et al 2004</xref>].</p>
        <table-wrap id="mga3.T.selected_opa3_variants" position="anchor" orientation="portrait">
          <label>Table 5.</label>
          <caption>
            <p>Selected <italic toggle="yes">OPA3</italic> Variants</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_mga3.T.selected_opa3_variants_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_b_mga3.T.selected_opa3_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.231T&#x0003e;C</td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.(=)&#x000a0;<sup>2</sup></td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_4" align="left" valign="middle" rowspan="6" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/156151425">NM_025136.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/13376717">NP_079412.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_1" align="left" valign="middle" rowspan="5" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.143-1G&#x0003e;C<break/>(IVS1-1G&#x0003e;C)</td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.277G&#x0003e;A</td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Gly93Ser&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.313C&#x0003e;G</td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Gln105Glu&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.320_337del</td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Gln108_Glu113del</td>
              </tr>
              <tr>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.415C&#x0003e;T</td>
                <td headers="hd_b_mga3.T.selected_opa3_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.Gln139Ter</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="mga3.TF.5">
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
            </fn>
            <fn id="mga3.TF.5.1">
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
            </fn>
            <fn id="mga3.TF.5.2">
              <p>1. Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="mga3.TF.5.3">
              <p>2. p.(=) designates that protein has not been analyzed, but no change is expected.</p>
            </fn>
            <fn id="mga3.TF.5.4">
              <p>3. Pathogenic variants associated with autosomal dominant optic atrophy and cataract </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">OPA3</italic> encodes a 179-amino acid (20-kd) protein that contains a mitochondrial targeting peptide, NRIKE, at amino acid residues 25-29 and is predicted to be exported to the mitochondrion [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>]. It is ubiquitously expressed, with highest expression in skeletal muscle and kidney. In the brain, the cerebral cortex, medulla, cerebellum, and frontal lobe have slightly increased expression [<xref ref-type="bibr" rid="mga3.REF.anikster.2001.1218">Anikster et al 2001</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The impact of the <italic toggle="yes">OPA3</italic> pathogenic variants on cell function is unknown. Homozygous acceptor splice site variant c.143-1G&#x0003e;C in <italic toggle="yes">OPA3</italic> with loss of function leads to typical <italic toggle="yes">OPA3</italic>-related methylglutaconic aciduria. </p>
        <p><bold>Animal model.</bold> An ENU-induced mutant mouse carrying the missense variant c.365T&#x0003e;C (p.Leu122Pro) of <italic toggle="yes">Opa3</italic> showed a normal phenotype in the heterozygous state. However, mice homozygous for this variant display severe multisystem disease including cardiomyopathy, movement disorder, and optic nerve involvement; life span is reduced [<xref ref-type="bibr" rid="mga3.REF.davies.2008.368">Davies et al 2008</xref>]. </p>
      </sec>
      <sec id="mga3.References">
        <title>References</title>
        <sec id="mga3.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="mga3.Literature_Cited.reflist0">
            <ref id="mga3.REF.anikster.2001.1218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews.</article-title>
                <source>Am J Hum Genet</source>
                <year>2001</year>
                <volume>69</volume>
                <fpage>1218</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">11668429</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.arn.2006.62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funanage</surname>
                    <given-names>VL</given-names>
                  </name>
                </person-group>
                <article-title>3-methylglutaconic aciduria disorders: the clinical spectrum increases.</article-title>
                <source>J Pediatr Hematol Oncol</source>
                <year>2006</year>
                <volume>28</volume>
                <fpage>62</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">16462574</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.barth.2004.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valianpour</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaz</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update.</article-title>
                <source>Am J Med Genet A</source>
                <year>2004</year>
                <volume>126A</volume>
                <fpage>349</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">15098233</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.copeliovitch.2001.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Copeliovitch</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arbel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harries</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bar-On</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soudry</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Musculoskeletal deformities in Behr syndrome.</article-title>
                <source>J Pediatr Orthop</source>
                <year>2001</year>
                <volume>21</volume>
                <fpage>512</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11433166</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.costeff.1998.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Costeff</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Apter</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prialnic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohles</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <article-title>Ineffectiveness of oral coenzyme Q10 supplementation in 3-methylglutaconic aciduria, type 3.</article-title>
                <source>Brain Dev</source>
                <year>1998</year>
                <volume>20</volume>
                <fpage>33</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9533558</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.davey.2006.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davey</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parboosingh</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLeod</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snyder</surname>
                    <given-names>FF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridge</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernier</surname>
                    <given-names>FP</given-names>
                  </name>
                </person-group>
                <article-title>Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition.</article-title>
                <source>J Med Genet</source>
                <year>2006</year>
                <volume>43</volume>
                <fpage>385</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">16055927</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.davies.2008.368">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yip</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollins</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piechota</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brownstein</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moat</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wride</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boulton</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Votruba</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>A missense mutation in the murine Opa3 gene models human Costeff syndrome.</article-title>
                <source>Brain</source>
                <year>2008</year>
                <volume>131</volume>
                <fpage>368</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">18222992</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.elpeleg.1994.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costeff</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joseph</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shental</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria in the Iraqi-Jewish 'optic atrophy plus' (Costeff) syndrome.</article-title>
                <source>Dev Med Child Neurol</source>
                <year>1994</year>
                <volume>36</volume>
                <fpage>167</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">7510656</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.gunayaygun.2005.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria: a common biochemical marker in various syndromes with diverse clinical features.</article-title>
                <source>Mol Genet Metab</source>
                <year>2005</year>
                <volume>84</volume>
                <fpage>1</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15719488</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.haimi.2006.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haimi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elhasid</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gershoni-Baruch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izraeli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Myeloid dysplasia in familial 3-methylglutaconic aciduria.</article-title>
                <source>J Pediatr Hematol Oncol</source>
                <year>2006</year>
                <volume>28</volume>
                <fpage>69</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">16462576</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.ho.2008.S419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Costeff optic atrophy syndrome: New clinical case and novel molecular findings.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2008</year>
                <volume>31</volume>
                <supplement>Suppl 2</supplement>
                <fpage>S419</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">18985435</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.ijlst.2002.1463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ijlst</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loupatty</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiter</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehnert</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria type I is caused by mutations in AUH.</article-title>
                <source>Am J Hum Genet</source>
                <year>2002</year>
                <volume>71</volume>
                <fpage>1463</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12434311</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.illsinger.2004.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Illsinger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucke</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>3-methylglutaconic aciduria type I in a boy with fever-associated seizures.</article-title>
                <source>Pediatr Neurol</source>
                <year>2004</year>
                <volume>30</volume>
                <fpage>213</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15033206</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.kleta.2002.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kleta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skovby</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria type III in a non-Iraqi-Jewish kindred: clinical and molecular findings.</article-title>
                <source>Mol Genet Metab</source>
                <year>2002</year>
                <volume>76</volume>
                <fpage>201</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12126933</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.neas.2005.525">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neas</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennetts</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirk</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baric</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>OPA3 mutation screening in patients with unexplained 3-methylglutaconic aciduria.</article-title>
                <source>J Inherit Metab Dis</source>
                <year>2005</year>
                <volume>28</volume>
                <fpage>525</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15902555</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.reynier.2004.e110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reynier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amati-Bonneau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verny</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olichon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guichet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemains</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malecaze</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malinge</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelletier</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dollfus</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belenguer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malthiery</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenaers</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract.</article-title>
                <source>J Med Genet</source>
                <year>2004</year>
                <volume>41</volume>
                <fpage>e110</fpage>
                <pub-id pub-id-type="pmid">15342707</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.straussberg.1998.54">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Straussberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brand</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gadoth</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>3-Methyl glutaconic aciduria in Iraqi Jewish children may be misdiagnosed as cerebral palsy.</article-title>
                <source>Neuropediatrics</source>
                <year>1998</year>
                <volume>29</volume>
                <fpage>54</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9553953</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.sweetman.2001.1">
              <mixed-citation publication-type="book">Sweetman L, Williams JC. Branched chain organic acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Basis of Inherited Disease.</italic> Vol 2. New York, NY: McGraw-Hill; 2001:2137-40.</mixed-citation>
            </ref>
            <ref id="mga3.REF.walsh.1999.251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conway</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayne</surname>
                    <given-names>PD</given-names>
                  </name>
                </person-group>
                <article-title>What is the origin of 3-methylglutaconic acid?</article-title>
                <source>J Inherit Metab Dis</source>
                <year>1999</year>
                <volume>22</volume>
                <fpage>251</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10384380</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.wortmann.2013a.923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013a</year>
                <volume>36</volume>
                <fpage>923</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23296368</pub-id>
              </element-citation>
            </ref>
            <ref id="mga3.REF.wortmann.2013b.913">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijtmans</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sass</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nouws</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Kaauwen</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleefstra</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tranebjaerg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isohanni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkuraya</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smuts</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinecke</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Westhuizen</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria-lessons from 50 genes and 977 patients.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013b</year>
                <volume>36</volume>
                <fpage>913</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">23355087</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="mga3.Suggested_Reading">
          <title>Suggested Reading </title>
          <ref-list id="mga3.Suggested_Reading.reflist0">
            <ref id="mga3.REF.vockley.2014.1">
              <mixed-citation publication-type="book">Vockley J, Zschocke J, Knerr I, Vockley CW, Gibson KM. Branched chain organic acidurias. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> 2015. New York, NY: McGraw-Hill. Chap 93.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="mga3.Chapter_Notes">
        <title>Chapter Notes</title>
        <p>
          <bold>Author History</bold>
        </p>
        <p>Yair Anikster, MD, PhD (2006-present)William A Gahl, MD, PhD; National Institutes of Health (2006-2013)Meral Gunay-Aygun, MD (2006-present)Marian Huizing, PhD (2013-present)</p>
        <sec id="mga3.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>19 December 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>31 March 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 July 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 April 2006 (mga) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="mga3.1.11" sec-type="figs-and-tables">
        <title/>
        <fig id="mga3.F1" position="float" orientation="portrait">
          <label>Figure 1.</label>
          <caption>
            <p>Metabolic pathway diagram showing branched-chain organic acid 3-MGC as an intermediate of leucine degradation and the mevalonate shunt pathway that links sterol synthesis with mitochondrial acetyl-CoA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mga3Fig1" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
